RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market

Core Viewpoint - RBC Capital initiated coverage of Eli Lilly (LLY) with an Outperform rating and a price target of $1,250, highlighting the company's potential to dominate the obesity market through 2030 [1] Group 1: Company Overview - Eli Lilly and Company (NYSE: LLY) is a pharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines for human health [3] Group 2: Market Position and Growth Potential - The obesity franchise of Eli Lilly is expected to lead the market, with investor sentiment remaining broadly positive despite some concerns over elevated expectations as the company approaches a $1 trillion market value [1] - Current consensus estimates are believed to materially undervalue Lilly's future growth potential, especially with transformative catalysts anticipated [1] Group 3: Product Performance - Eli Lilly's experimental weight-loss pill, orforglipron, demonstrated stronger effectiveness in controlling blood sugar and reducing weight compared to Novo Nordisk's Rybelsus, lowering blood sugar levels by 2.2% versus 1.4% and resulting in an average weight loss of 8.9 kg compared to 5 kg for Rybelsus [2] - However, orforglipron also had a higher incidence of side effects, with 58% of patients reporting mild-to-moderate side effects compared to 45% for Rybelsus, and a higher discontinuation rate due to side effects [1][2]